This article is more than 5 years old. Information may no longer be current.

VIDEO: Some women with early-stage breast cancer can safely avoid adjuvant chemotherapy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW ORLEANS — Hatem Soliman, MD, assistant member of the women’s oncology and breast cancer department at Moffitt Cancer Center, discusses the implications of the results from the randomized phase 3 MINDACT trial, presented at the American Association for Cancer Research Annual Meeting.

Results showed a genomic test called MammaPrint can help predict which patients with early-stage breast cancer will derive the most benefit from adjuvant chemotherapy.

“There are women who are lymph node-positive who we would traditionally consider as being high-risk, but when they had a low-risk MammaPrint (test result), they did very well and had over a 95% chance of not having a recurrence of their disease,” Soliman told HemOnc Today. “Women with low-risk MammaPrint tests can likely safely avoid additional chemotherapy after their surgical treatment and still have excellent outcomes.”